WO2022092198A1 - 免疫隔離デバイス - Google Patents
免疫隔離デバイス Download PDFInfo
- Publication number
- WO2022092198A1 WO2022092198A1 PCT/JP2021/039818 JP2021039818W WO2022092198A1 WO 2022092198 A1 WO2022092198 A1 WO 2022092198A1 JP 2021039818 W JP2021039818 W JP 2021039818W WO 2022092198 A1 WO2022092198 A1 WO 2022092198A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- layer
- hydrogel
- immunoisolation
- immune
- Prior art date
Links
- 239000012528 membrane Substances 0.000 claims abstract description 227
- 239000000463 material Substances 0.000 claims abstract description 54
- 239000000017 hydrogel Substances 0.000 claims description 121
- 239000000835 fiber Substances 0.000 claims description 100
- 238000002955 isolation Methods 0.000 claims description 58
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 42
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 32
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 31
- 230000035699 permeability Effects 0.000 claims description 31
- 229920000642 polymer Polymers 0.000 claims description 30
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 claims description 21
- 102000004877 Insulin Human genes 0.000 claims description 21
- 108090001061 Insulin Proteins 0.000 claims description 21
- 229940125396 insulin Drugs 0.000 claims description 21
- 230000001900 immune effect Effects 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- 239000008103 glucose Substances 0.000 claims description 19
- 210000000987 immune system Anatomy 0.000 claims description 19
- 238000002834 transmittance Methods 0.000 claims description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 13
- 230000009471 action Effects 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 8
- 230000009545 invasion Effects 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 abstract description 15
- 239000013543 active substance Substances 0.000 abstract description 13
- 238000009792 diffusion process Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 4
- 239000010410 layer Substances 0.000 description 175
- 210000004027 cell Anatomy 0.000 description 68
- 239000000499 gel Substances 0.000 description 28
- 239000004745 nonwoven fabric Substances 0.000 description 26
- 239000007943 implant Substances 0.000 description 22
- 239000011148 porous material Substances 0.000 description 21
- -1 polyethylene Polymers 0.000 description 19
- 239000000243 solution Substances 0.000 description 14
- HUOOMAOYXQFIDQ-UHFFFAOYSA-N isoginkgetin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)OC)=C2O1 HUOOMAOYXQFIDQ-UHFFFAOYSA-N 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 230000008595 infiltration Effects 0.000 description 12
- 238000001764 infiltration Methods 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 239000002131 composite material Substances 0.000 description 8
- 239000002356 single layer Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 229920001567 vinyl ester resin Polymers 0.000 description 7
- 230000000975 bioactive effect Effects 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 238000005191 phase separation Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 238000007127 saponification reaction Methods 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 229920001290 polyvinyl ester Polymers 0.000 description 4
- 229940117958 vinyl acetate Drugs 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000002657 fibrous material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000003466 welding Methods 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 2
- 239000008131 herbal destillate Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- FSQQTNAZHBEJLS-OWOJBTEDSA-M (e)-4-amino-4-oxobut-2-enoate Chemical compound NC(=O)\C=C\C([O-])=O FSQQTNAZHBEJLS-OWOJBTEDSA-M 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- ZMKVBUOZONDYBW-UHFFFAOYSA-N 1,6-dioxecane-2,5-dione Chemical compound O=C1CCC(=O)OCCCCO1 ZMKVBUOZONDYBW-UHFFFAOYSA-N 0.000 description 1
- LAYAKLSFVAPMEL-UHFFFAOYSA-N 1-ethenoxydodecane Chemical compound CCCCCCCCCCCCOC=C LAYAKLSFVAPMEL-UHFFFAOYSA-N 0.000 description 1
- QJJDJWUCRAPCOL-UHFFFAOYSA-N 1-ethenoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOC=C QJJDJWUCRAPCOL-UHFFFAOYSA-N 0.000 description 1
- OVGRCEFMXPHEBL-UHFFFAOYSA-N 1-ethenoxypropane Chemical compound CCCOC=C OVGRCEFMXPHEBL-UHFFFAOYSA-N 0.000 description 1
- STMDPCBYJCIZOD-UHFFFAOYSA-N 2-(2,4-dinitroanilino)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O STMDPCBYJCIZOD-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- PGYJSURPYAAOMM-UHFFFAOYSA-N 2-ethenoxy-2-methylpropane Chemical compound CC(C)(C)OC=C PGYJSURPYAAOMM-UHFFFAOYSA-N 0.000 description 1
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 1
- TXURIHBPMLYETE-UHFFFAOYSA-N 2-methylprop-2-enoic acid;propane-1-sulfonic acid Chemical compound CC(=C)C(O)=O.CCCS(O)(=O)=O TXURIHBPMLYETE-UHFFFAOYSA-N 0.000 description 1
- RUMACXVDVNRZJZ-UHFFFAOYSA-N 2-methylpropyl 2-methylprop-2-enoate Chemical compound CC(C)COC(=O)C(C)=C RUMACXVDVNRZJZ-UHFFFAOYSA-N 0.000 description 1
- CFVWNXQPGQOHRJ-UHFFFAOYSA-N 2-methylpropyl prop-2-enoate Chemical compound CC(C)COC(=O)C=C CFVWNXQPGQOHRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical compound ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- HETCEOQFVDFGSY-UHFFFAOYSA-N Isopropenyl acetate Chemical compound CC(=C)OC(C)=O HETCEOQFVDFGSY-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical group NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- CNCOEDDPFOAUMB-UHFFFAOYSA-N N-Methylolacrylamide Chemical compound OCNC(=O)C=C CNCOEDDPFOAUMB-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004962 Polyamide-imide Substances 0.000 description 1
- 239000004693 Polybenzimidazole Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- KTVZJASWYJPWEV-UHFFFAOYSA-M [PH2]([O-])=O.[Li+] Chemical compound [PH2]([O-])=O.[Li+] KTVZJASWYJPWEV-UHFFFAOYSA-M 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DMLAVOWQYNRWNQ-UHFFFAOYSA-N azobenzene Chemical compound C1=CC=CC=C1N=NC1=CC=CC=C1 DMLAVOWQYNRWNQ-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical class NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- LPUZTLKYAOOFDX-QXMHVHEDSA-N ethenyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC=C LPUZTLKYAOOFDX-QXMHVHEDSA-N 0.000 description 1
- YCUBDDIKWLELPD-UHFFFAOYSA-N ethenyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC=C YCUBDDIKWLELPD-UHFFFAOYSA-N 0.000 description 1
- WNMORWGTPVWAIB-UHFFFAOYSA-N ethenyl 2-methylpropanoate Chemical compound CC(C)C(=O)OC=C WNMORWGTPVWAIB-UHFFFAOYSA-N 0.000 description 1
- CMDXMIHZUJPRHG-UHFFFAOYSA-N ethenyl decanoate Chemical compound CCCCCCCCCC(=O)OC=C CMDXMIHZUJPRHG-UHFFFAOYSA-N 0.000 description 1
- GLVVKKSPKXTQRB-UHFFFAOYSA-N ethenyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC=C GLVVKKSPKXTQRB-UHFFFAOYSA-N 0.000 description 1
- GFJVXXWOPWLRNU-UHFFFAOYSA-N ethenyl formate Chemical compound C=COC=O GFJVXXWOPWLRNU-UHFFFAOYSA-N 0.000 description 1
- UJRIYYLGNDXVTA-UHFFFAOYSA-N ethenyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC=C UJRIYYLGNDXVTA-UHFFFAOYSA-N 0.000 description 1
- LZWYWAIOTBEZFN-UHFFFAOYSA-N ethenyl hexanoate Chemical compound CCCCCC(=O)OC=C LZWYWAIOTBEZFN-UHFFFAOYSA-N 0.000 description 1
- AFSIMBWBBOJPJG-UHFFFAOYSA-N ethenyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC=C AFSIMBWBBOJPJG-UHFFFAOYSA-N 0.000 description 1
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
- ZQZUENMXBZVXIZ-UHFFFAOYSA-N ethenyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC=C ZQZUENMXBZVXIZ-UHFFFAOYSA-N 0.000 description 1
- NKSJNEHGWDZZQF-UHFFFAOYSA-N ethenyl(trimethoxy)silane Chemical compound CO[Si](OC)(OC)C=C NKSJNEHGWDZZQF-UHFFFAOYSA-N 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- XUCNUKMRBVNAPB-UHFFFAOYSA-N fluoroethene Chemical compound FC=C XUCNUKMRBVNAPB-UHFFFAOYSA-N 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 description 1
- DNTMQTKDNSEIFO-UHFFFAOYSA-N n-(hydroxymethyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCO DNTMQTKDNSEIFO-UHFFFAOYSA-N 0.000 description 1
- RQAKESSLMFZVMC-UHFFFAOYSA-N n-ethenylacetamide Chemical compound CC(=O)NC=C RQAKESSLMFZVMC-UHFFFAOYSA-N 0.000 description 1
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 description 1
- SWPMNMYLORDLJE-UHFFFAOYSA-N n-ethylprop-2-enamide Chemical compound CCNC(=O)C=C SWPMNMYLORDLJE-UHFFFAOYSA-N 0.000 description 1
- YPHQUSNPXDGUHL-UHFFFAOYSA-N n-methylprop-2-enamide Chemical compound CNC(=O)C=C YPHQUSNPXDGUHL-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- HMZGPNHSPWNGEP-UHFFFAOYSA-N octadecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(C)=C HMZGPNHSPWNGEP-UHFFFAOYSA-N 0.000 description 1
- FSAJWMJJORKPKS-UHFFFAOYSA-N octadecyl prop-2-enoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C=C FSAJWMJJORKPKS-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- HVAMZGADVCBITI-UHFFFAOYSA-M pent-4-enoate Chemical compound [O-]C(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-M 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002285 poly(styrene-co-acrylonitrile) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002312 polyamide-imide Polymers 0.000 description 1
- 229920002480 polybenzimidazole Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229940117828 polylactic acid-polyglycolic acid copolymer Drugs 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920006380 polyphenylene oxide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- NHARPDSAXCBDDR-UHFFFAOYSA-N propyl 2-methylprop-2-enoate Chemical compound CCCOC(=O)C(C)=C NHARPDSAXCBDDR-UHFFFAOYSA-N 0.000 description 1
- PNXMTCDJUBJHQJ-UHFFFAOYSA-N propyl prop-2-enoate Chemical compound CCCOC(=O)C=C PNXMTCDJUBJHQJ-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000007870 radical polymerization initiator Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000006903 response to temperature Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- SJMYWORNLPSJQO-UHFFFAOYSA-N tert-butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C)(C)C SJMYWORNLPSJQO-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000004634 thermosetting polymer Substances 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- KOZCZZVUFDCZGG-UHFFFAOYSA-N vinyl benzoate Chemical compound C=COC(=O)C1=CC=CC=C1 KOZCZZVUFDCZGG-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/02—Membranes; Filters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
Definitions
- Immune isolation devices have been developed as a means of performing cell transplantation therapy without the need for administration of immunosuppressive drugs.
- macroencapsulation immunoisolation devices are capable of identifying transplantation sites and exchanging devices in the event of iPS cell-derived somatic cell transplantation or functional deterioration of transplanted cells, where there is concern about the risk of canceration. It is said to be an effective method.
- the functions required for a macroencapsulated immunoseparation device are that cells or cell clusters can be dispersed and fixed without being uniformly associated, that oxygen and / or nutritional components can be easily permeated into transplanted cells, and that they are necessary for therapeutic effects.
- the target physiologically active substances (cytokines, hormones, growth factors, etc.) released by the cells can be easily released according to the cell response, and the immune response cells and the immune response factors are not allowed to permeate, and the cells are transplanted. It is important that the device has excellent biocompatibility and is less likely to cause inflammatory reactions such as adhesion to surrounding tissues and granulation.
- the present invention provides a macro-encapsulated immuno-isolation device suitable for easy removal of the device in long-term transplantation, no damage to the device, maintenance of immuno-isolation effect, and improvement of diffusion efficiency of physiologically active substances required for transplantation.
- One purpose is to provide.
- the present invention has excellent biocompatibility without interfering with the engraftment of implants such as cells and cell clumps, maintains immunoisolation, reduces the diffusion distance in the device, and at the same time improves durability.
- the other purpose is to provide the invention to be achieved.
- the present invention provides the following immunological isolation devices.
- An immunoisolation device comprising an embedding chamber for a transplant to be implanted, wherein the embedding chamber is covered with an immunoisolation membrane.
- the immunoisolation membrane comprises at least two selected from the group consisting of a fibrous structure, a porous membrane and a hydrogel.
- the immune isolation membrane is a multi-layered membrane including at least two layers selected from the group consisting of a fibrous structure layer, a porous membrane layer and a hydrogel layer.
- the immune isolation device according to any one of [1] to [3], wherein the immune isolation membrane suppresses the invasion of immune response cells and immune system humoral factors into the embedding chamber. .. [5]
- the immune isolation membrane blocks the permeation of immune-responsive cells, the transmittance of insulin and glucose is 50% or more, and the permeability of immune system humoral factors is 30% or less [1].
- the immunoisolation device according to any one of [4].
- [10] to [8] include the immunoseparator membrane in which a fiber structure is used as a base material, a polymer raw material is applied to the fiber structure, and a porous film is formed between the short fibers of the fiber structure.
- the immunoseparator according to any one of the following items.
- the immunoseparator film is formed by applying a hydrosol solution directly to the fiber structure using the fiber structure as a base material and hydrogelizing the fiber structure by heat, temperature, light or chemical action.
- the immunological isolation device according to any one of [10].
- the above-mentioned immunoseparator membrane which comprises a porous membrane as a base material, a hydrosol solution directly applied to the porous membrane, and hydrogelled by heat, temperature, light or chemical action, [1] to The immunoseparation device according to any one of [9].
- the hydrogel is composed of a polyvinyl alcohol-based polymer.
- the immunoisolation device according to any one of [1] to [14], wherein the outermost surface of the immunoisolation membrane is composed of an ethylene-vinyl alcohol copolymer.
- the outermost surface of the immunoisolation membrane is a fiber structure of an ethylene-vinyl alcohol copolymer, and the surface is smoothly compressed.
- Immune isolation device as described in section.
- the immunoisolation device according to any one of [1] to [16], wherein the immunoisolation membrane has a thickness of 10 ⁇ m or more and 300 ⁇ m or less.
- the immune isolation device according to any one of [1] to [17], wherein the thickness of the multilayer layer of the hydrogel constituting the immunoisolation membrane and the porous membrane is 10 ⁇ m or more and 300 ⁇ m or less.
- the immune isolation device according to any one of [1] to [18], wherein the multi-layer thickness of the fibrous structure constituting the immunoisolation membrane and the porous membrane is 10 ⁇ m or more and 300 ⁇ m or less.
- the immunological isolation device according to any one of [1] to [19], wherein the multi-layer thickness of the fibrous structure constituting the immunoisolation membrane and the hydrogel is 10 ⁇ m or more and 300 ⁇ m or less.
- an immunoisolation device that realizes both reduction of diffusion distance effective for improving the transmittance of substances such as physiologically active substances and nutrients and improvement of durability that can withstand long-term transplantation. can.
- FIG. 1 Perspective view of a bag-shaped immunological isolation device
- Cross section of tubular immunoisolation device Cross-sectional view of a two-layer immunoisolation membrane consisting of a porous membrane and a non-woven fabric
- Cross-sectional view of an immunoseparator membrane in which a non-woven fabric and hydrogel are multi-layered Cross-sectional view of an immunoisolation membrane having a three-layer structure consisting of a hydrogel layer, a non-woven fabric layer, and a porous membrane layer.
- the immunoisolation device of the present invention includes an embedding chamber and an immunoseparation membrane capable of embedding an implant, and the embedding chamber is covered with the immunoseparation membrane to embed immune cells and cytokines. Invasion into the room can be suppressed.
- the immunoseparator membrane comprises at least two selected from the group consisting of fibrous structures, porous membranes and hydrogels.
- fiber structure examples include non-woven fabrics, woven fabrics, and knitted fabrics, and non-woven fabrics are preferable.
- material of the fiber structure gelatin, collagen, chitin, chitosan, fibronectin, dextran, cellulose, polyethylene (PE), polypropylene (PP), polyurethane, polyamide, polyester, polyvinyl alcohol (PVA), ethylene-vinyl alcohol co-weight.
- PVA modified with monomers such as coalescence, polylactic acid, polyglycolic acid, polylactic acid-polyglycolic acid copolymer, methacrylic-modified PVA, acrylic-modified PVA, polycaprolactone, polyglycerol sebacic acid, polyhydroxyalkanoic acid, poly Examples thereof include butylene succinate, polyvinylene carbonate, cellulose diacetate, cellulose triacetate, methyl cellulose, propyl cellulose, benzyl cellulose, carboxymethyl cellulose, fibroin, silk and the like.
- the fiber structure layer may be composed of one kind of fiber structure layer, or two or more kinds of fiber structure layers may be laminated to form one fiber structure layer. Further, when the immunoseparation device of the present invention contains two or more kinds of fiber structure layers, the fiber structure layers may be directly laminated, and a porous membrane layer or a hydro may be formed between the two fiber structure layers. A gel layer may be interposed.
- the thickness of the fiber structure layer is not particularly limited, but is preferably 10 ⁇ m or more and 290 ⁇ m or less, and more preferably 15 ⁇ m to 150 ⁇ m.
- Hydrosols for producing "hydrogels” include, for example, sol that gels in the presence of metal ions to form a hydrogel, sol that gels in response to temperature to form a hydrogel, and responds to pH. Examples thereof include a sol that gels to form a hydrogel, and a sol that forms a hydrogel in response to light.
- Metal ions and pH are examples of chemical action. In order to gel these hydrosols, depending on the characteristics of the gel used, metal ions are brought into contact, the temperature is adjusted to the gelling conditions, the pH is adjusted to the gelling conditions, and the light of the gelling conditions is applied. Operations such as irradiating and applying a magnetic field under gelation conditions may be performed.
- Hydrogels that gel in the presence of metal ions include alginate gels that gel in the presence of divalent or trivalent metal ions, preferably alkaline earth metal ions such as calcium and magnesium ions; calcium ions and / Or a carrageenan gel that gels in the presence of potassium ions; an acrylic acid-based synthetic gel that gels in the presence of sodium ions, and the like.
- alkaline earth metal ions such as calcium and magnesium ions
- calcium ions and / Or a carrageenan gel that gels in the presence of potassium ions
- an acrylic acid-based synthetic gel that gels in the presence of sodium ions, and the like.
- a temperature-responsive hydrogel obtained by cross-linking poly (N-isopropylacrylamide) with polyethylene glycol, methyl cellulose, hydroxypropyl cellulose, a copolymer of lactic acid and ethylene glycol, and polyethylene glycol.
- a triblock copolymer of polypropylene oxide (trade name: Pluronic (registered trademark), poloxamer), agarose, polyvinyl alcohol and the like can be mentioned.
- pH-responsive hydrogel examples include alginate gel, chitosan gel, carboxymethyl cellulose gel, and acrylic acid-based synthetic gel.
- Photoresponsive hydrogels include synthetic gels that combine azobenzene and cyclodextrin in the skeleton, gels consisting of supermolecules with fumaric acid amide as a spacer, gels that are crosslinked or bonded via a nitrobenzyl group, and modified polyvinyl alcohol. Examples include gels made of.
- the thickness of the hydrogel layer is not particularly limited, but is preferably 10 ⁇ m to 290 ⁇ m, more preferably 20 ⁇ m to 200 ⁇ m, and further preferably 30 ⁇ m to 100 ⁇ m.
- the hydrogel layer may be composed of one kind of hydrogel layer, or two or more kinds of hydrogel layers may be laminated to form one hydrogel layer. Further, when the immunoseparation device of the present invention contains two or more hydrogel layers, the hydrogel layers may be directly laminated, and a porous membrane layer or a fiber structure layer may be formed between the two hydrogel layers. It may be intervened.
- Hydrogel can regulate the transmittance, intensity, etc. of nutritional substances such as glucose, physiologically active substances such as insulin, and humoral factors of the immune system by cross-linking.
- the "porous film” is a film having a plurality of pores, and the porous film can be confirmed by a scanning electron microscope (SEM) image or a transmission electron microscope (TEM) image of the cross section of the film. ..
- the thickness of the porous membrane is not particularly limited, but is preferably 15 ⁇ m to 290 ⁇ m, and more preferably 30 ⁇ m to 150 ⁇ m.
- the average pore size of the porous membrane is not particularly limited, but is preferably 0.01 ⁇ m to 10 ⁇ m, more preferably 0.01 ⁇ m to 5 ⁇ m, and even more preferably 0.01 to 3 ⁇ m.
- the average pore size can be determined from the SEM image or the TEM image.
- the maximum pore size of the porous membrane is not particularly limited, but is preferably 0.01 ⁇ m to 10 ⁇ m, more preferably 0.01 ⁇ m to 5 ⁇ m, and further preferably 0.01 ⁇ m to 4 ⁇ m.
- the maximum pore size is within the above range, the invasion of immune response cells into the embedding chamber is suppressed, and nutritional substances such as carbon sources such as amino acids, vitamins, inorganic salts and glucose, oxygen, carbon dioxide and cytokines. , Hormones, insulin and other physiologically active substances can be sufficiently permeated.
- the average pore diameter or the maximum pore diameter can be determined from the SEM captured image or the TEM captured image.
- the porous membrane contains a polymer and is substantially composed of the polymer.
- the polymer forming the porous membrane is preferably biocompatible.
- polymers include thermoplastic or thermosetting polymers.
- the polymer may be biocompatible.
- Specific examples of the polymer include ethylene-vinyl alcohol copolymer, polysulfone, cellulose acylate such as cellulose acetate, nitrocellulose, sulfonated polysulfone, polyethersulfone, polyacrylonitrile, styrene-acrylonitrile copolymer, and styrene-butadiene copolymer.
- Ethylene-vinylacetate copolymer saken polyvinyl alcohol, polycarbonate, organosiloxane-polypolypolymer, polyester carbonate, organopolysiloxane, polyphenylene oxide, polyamide, polyimide, polyamideimide, polybenzimidazole, polytetrafluoroethylene (PTFE), etc. Can be mentioned. These may be homopolymers, copolymers, polymer blends, polymer alloys and the like from the viewpoints of solubility, optical properties, electrical properties, strength, elasticity and the like.
- the polymer constituting the porous membrane may contain a hydrophilic polymer such as polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxyethyl cellulose and polyethylene glycol. Biocompatibility can be improved by combining a hydrophilic polymer and a hydrophobic polymer.
- the porous membrane is preferably a membrane formed from one composition as a single layer, and preferably does not have a laminated structure of a plurality of layers.
- the porous membrane layer may be composed of one kind of porous membrane layer, or two or more kinds of porous membrane layers may be laminated to form one porous membrane layer. Further, when the immunoisolation device of the present invention contains two or more porous membrane layers, the porous membrane layers may be directly laminated, and a hydrogel layer or a fiber structure may be formed between the two porous membrane layers. Layers may be interposed.
- the permeation of glucose, insulin, immune system humoral factors, etc. in the immunoisolation membrane is a known concentration in chamber A under stirring at 37 ° C. with the porous membrane sandwiched between two glass chambers of the same volume. It can be measured by adding a sample solution of insulin or the like and quantifying the amount of insulin or the like contained in the solution sampled from the chamber B after a certain period of time by using ELISA or the like.
- the liquid volumes in chambers A and B are adjusted to be equal when the sample solution is placed in chamber A.
- the transmittance of glucose, insulin, immune system humoral factors, etc. in the immune isolation membrane is the concentration at which the permeation amount of each substance into chamber B measured by the above method after 24 hours reaches an equilibrium, that is, put into chamber A.
- the permeability of insulin and glucose of the immunoisolation membrane of the present invention is preferably 50% or more, more preferably 90% or more, still more preferably 95% or more.
- the transmittance of the immune system humoral factor of the immune isolation membrane of the present invention is preferably 30% or less, more preferably 10% or less.
- the immunoseparator membrane of the present invention contains two or more kinds selected from the group consisting of a fibrous structure, a hydrogel, and a porous membrane, and may contain all three kinds, a fibrous structure, a hydrogel, and a porous membrane. Each form a layer, the boundaries of which may be clearly separated, or the boundaries of the two layers may not be clear, and the two or three types may be integrated to form one layer. May be good.
- the immunoseparator membrane containing two types of fiber structure and hydrogel may be a multi-layered immunoseparator membrane in which the fibrous structure layer and the hydrogel layer are clearly separated, and the fibrous structure layer and the hydrogel may be used.
- the fiber structure layer and the hydrogel may be mixed between the layers, or the fiber structure and the hydrogel may be completely integrated to form one layer.
- the immunoseparator membrane containing two types of fibrous structure and porous membrane may be a multi-layered immunoseparator membrane in which the fibrous structure layer and the porous membrane layer are clearly separated, and the fibrous structure layer and the porous membrane are porous.
- a layer in which a fiber structure layer and a porous membrane are mixed may be provided between the membrane layers, or the fiber structure and the porous membrane may be completely integrated to form one layer.
- the immunoseparator membrane containing two types of hydrogel and porous membrane may be a multi-layered immunoseparator membrane in which the hydrogel layer and the porous membrane layer are clearly separated, and the hydrogel layer and the porous membrane layer may be formed.
- a layer in which a hydrogel layer and a porous membrane are mixed may be provided between them, or the hydrogel and the porous membrane may be completely integrated to form one layer.
- the immunoisolation membrane has multiple layers, those layers may be adhered by an adhesive, heat, pressure, etc., and if the adjacent layers are made of a highly compatible material, the layers are sequentially formed. It can be adhered by forming.
- the thickness of the immunoisolation membrane is not particularly limited, but is preferably 10 ⁇ m or more and 300 ⁇ m or less.
- the tensile strength of the immunoisolation membrane is preferably 1 MPa or more.
- the tensile strength can be measured according to JIS K 7127; 1999.
- the outer layer of the immunoisolation membrane may be any of a fibrous structure, a hydrogel, and a porous membrane, and may be a mixture of these two or three types.
- the inner layer of the immunoisolation membrane may be any of a fibrous structure, a hydrogel, and a porous membrane, and two or three of these may be mixed.
- the outer layer of the immunoisolation membrane is preferably biocompatible in order to prevent it from being recognized as a foreign substance.
- the immunoisolation membrane is required to have the permeability necessary to allow sufficient oxygen and nutrients to permeate the internal implant.
- the introduction of the implant into the embedding chamber may be performed using a device such as a syringe that injects a suspension of the implant, from which an opening is provided in the immunoisolation membrane through which the implant is introduced. It may be introduced into the embedding chamber and then closed to block the invasion of immune response cells and immune system humoral factors through the opening. Since oxygen and nutrients can permeate through immunoisolation membranes other than the openings, the openings can be closed to suppress the permeation of substances, including nutrients.
- a transplant with reduced function of the embedding chamber is taken out, a new functional transplant is introduced, this operation is repeated, and the immuno-isolation device is repeated.
- the immuno-isolation device may be used to introduce the implant or the immunoisolation device may be removed with the implant.
- the immuno-isolated device When an immuno-isolated device is indwelled and only the transplant is exchanged, the immuno-isolated device is provided with a tubular access port that can be accessed from the outside in advance, and the end of the access port is placed externally or subcutaneously for access. It is possible to exchange implants through the port. It is important that the joint between the access port and the device is joined with a highly biocompatible resin such as an ethylene-vinyl alcohol copolymer without leakage.
- infection control measures are taken by using a sterilized injection needle or catheter under infection control measures, and after the replacement work is completed, sealing the end part with a biocompatible material. It is important to take.
- the immunoisolation membrane of the present invention Since the immunoisolation membrane of the present invention has sufficient strength, is stably present in the recipient's body, and can suppress the invasion of immunocompetent cells into the embedding chamber, the implantee in the embedding chamber. Invasion into the recipient's body can be suppressed at the same time. Therefore, even if the transplanted product is derived from iPS cells, which may become cancerous, it can be used with confidence.
- a fiber structure having excellent durability is used as a base material, and a polymer porous film or hydrogel is formed on the fiber structure, or a porous film and hydrogel are formed on the fiber structure.
- the immunoisolation device of the preferred embodiment of the present invention preferably has a shape-retaining property for having sufficient strength in vivo in the preferred embodiment.
- immune response cells include macrophages, cytotoxic T cells, natural killer cells, dendritic cells, helper T cells, and examples of immune system humoral factors include antibodies, complement, and cytokines.
- the immunoisolation device of the preferred embodiment of the present invention is bag-shaped, tubular, cylindrical, square-cylindrical, spherical, cubic, rectangular parallelepiped, sheet-shaped or hollow filament-shaped, and embeds cells for transplantation therein. ..
- the implant may be a cell, a cell mass, a cell sheet, or a graft, and a bioactive substance such as an enzyme, hormone, cytokine, or drug other than cells can also be used.
- Preferred cells, cell clumps, and grafts are those that release bioactive substances out of the immunological isolation device. That is, cells, cell masses, and grafts contain cells that produce physiologically active substances.
- a particularly preferable immunoisolation device of the present invention is composed of any one of the following four types of multilayer structures (i) to (iv).
- a porous film is formed on the fiber structure using the fiber structure or hydrogel as a base material. or
- the fiber structure is impregnated with hydrogel to form. or
- hydrogel is impregnated on the porous membrane. or
- a porous film is formed and a hydrogel is further formed.
- the fiber structure, porous membrane and hydrogel are materials with excellent safety and biocompatibility.
- the control of the material transmittance can be controlled by the pore size of the porous membrane or the strength and degree of cross-linking of the hydrogel.
- the pore size of the porous membrane should be smaller than the size that does not permeate cells, and hydrogel does not suppress the permeation of physiologically active substances and can suppress the permeation of immune response factors such as cells and antibodies. desirable.
- the immunoisolation membrane be made of a material with excellent biocompatibility.
- the biocompatible material is the contact surface of the transplant side, that is, the outermost layer in contact with the transplant site of the recipient.
- the material having excellent biocompatibility include an ethylene-vinyl alcohol copolymer.
- the schematic diagram of the device shows a bag-shaped (FIG. 1) or tubular (FIG. 2) molded immune isolation membrane.
- the sac-shaped device (Fig. 1) uses the multi-layered immunoprotective membranes (a1 and a2) shown below at a fixed distance (a4) to secure space for the embedding chamber, and heat, ultrasonic waves, and high frequencies. , It is molded by welding (a3) with an electron beam or the like. A spacer may be provided to secure a certain distance (a4).
- the tubular device (Fig. 2) is composed of each immunoseparator membrane (b1, b2, b3) formed into a tubular shape, and the embedding chamber is embedded in the tubular interior (b4), and both ends of the tubular tube are heated. It is molded by welding and sealing with ultrasonic waves, high frequency, electron beam, etc.
- FIGS. 3-9 the outermost layer is in contact with the transplantation site and the innermost layer is in contact with the embedding chamber.
- 3 and 4 show the multi-layering of the porous membrane (1) and the fiber structure (2).
- FIG. 3 has a two-layer structure in which the porous membrane (1) is the outer layer and the fiber structure (2) is the inner layer, the outermost layer (3) is in contact with the transplanted site, and the innermost layer (4) is encapsulated. It touches the buried room.
- FIG. 4 has a two-layer structure in which the fiber structure (6) is the outer layer and the porous membrane (5) is the inner layer, the outermost layer (7) is in contact with the transplanted site, and the innermost layer (8) is encapsulated. It touches the buried room.
- FIG. 5 shows a composite layer in which a porous film (10) is directly coated on a base material of a fiber structure (9).
- the outermost layer surface (11) has a porous film (10) covering the fiber structure (9), and the innermost layer surface (12) is either the porous film (10) or the fiber structure (9). But it's okay.
- FIG. 6 shows the multi-layering of the porous membrane (13) and the hydrogel (15).
- the hydrogel (15) is impregnated and immobilized (14) on the porous membrane (13), the outermost layer surface (16) is composed of the porous membrane (10), and the innermost layer surface is the hydrogel (14). It is composed of 17).
- FIG. 7 shows the multi-layering of the fiber structure (18) and the hydrogel (19).
- the hydrogel (19) is impregnated and fixed to the fiber structure (18)
- the outermost layer surface (20) is composed of the fiber structure (18)
- the innermost layer surface (21) is attached to the hydrogel (19). It is composed of.
- FIG. 8 shows a composite layer in which the multilayer devices of FIGS. 3 and 7 are composited, and the outermost layer surface (22) is composed of a porous film and the innermost layer surface (23) is composed of hydrogel.
- FIG. 9 shows a composite layer in which the multilayer devices of FIGS. 5 and 6 are composited, and the outermost layer surface (24) is composed of a porous film and the innermost layer surface (25) is composed of hydrogel.
- the present invention relates to a transplant device used for cell transplantation therapy and the like, and more particularly to an immunoisolation device for protecting against immune rejection of a transplanted object.
- the immunoisolation device is supposed to be used mainly for cell transplantation therapy as a product for regenerative medicine, but it can also be applied to transplantation of bioactive substances such as enzymes, hormones and drugs other than cells.
- the device conceptual diagram has a bag-like or tubular shape, and an object to be transplanted, such as a cell or a cell mass, is embedded as an embedding chamber inside the device.
- the embedding chamber refers to an object to be transplanted such as a cell or a cell mass uniformly dispersed and fixed to a fixing material inside the embedding chamber.
- the fixing material may be the above-mentioned hydrogel or hydrosol, or may be a cell scaffold material such as collagen fiber.
- a person who has been sterilized can be used for all of the hydrosol, hydrogel, and cell scaffold material.
- the fixation material may be present in an embedding chamber surrounded by an immunoisolation membrane prior to the introduction of the implant, and encloses the implant and the fixation material in an immunoisolation device composed of the immunoisolation membrane. It may be introduced later into the buried room.
- the immunoseparator membrane of the present invention is a porous membrane alone or a combination of a porous membrane and a fiber structure
- hydrogel as a fixing material. This is because hydrogels can effectively suppress contact between immune system humoral factors and the implant.
- the immunoseparator membrane is a multi-layer (two or three layers) in which a porous membrane and / or a fibrous structure and a hydrogel are combined, the hydrogel in the immunoseparator membrane invades the immune system humoral factor.
- the fixing material may be a hydrogel, and a scaffold material capable of dispersing and fixing an implant other than the hydrogel can be widely used.
- the embedding chamber can be provided with a role of uniformly immobilizing cells by adjusting a fixing material such as hydrogel, and also preventing the invasion of immune system humoral factors such as antibodies into the implant. ..
- the immunoisolation membrane shown in FIGS. 3 to 9 is composed of a combination of a plurality of materials shown below.
- the outermost layer is in contact with the recipient's transplant site tissue and the innermost layer is in contact with the embedding chamber.
- these immunoisolation membranes they are molded into a bag shape (Fig. 1) or tubular (Fig. 2), and an embedding chamber in which cells or cell masses to be transplanted are fixed is embedded inside, and an immunoisolation device is used. And.
- 3 and 4 show the multi-layering of the porous membrane (1, 5) and the fiber structure (2, 6). It is an immunoisolation membrane formed by forming a porous membrane layer on a fiber structure layer.
- the thickness of the multilayer of the fibrous structure constituting the immunoisolation membrane and the porous membrane is not particularly limited, but is preferably 10 ⁇ m or more and 300 ⁇ m or less.
- FIG. 3 has a two-layer structure in which the porous membrane (1) is the outer layer and the fiber structure (2) is the inner layer, the outermost layer (3) is in contact with the transplanted site, and the innermost layer (4) is encapsulated. It touches the buried room.
- FIG. 4 has a two-layer structure in which the fiber structure (6) is the outer layer and the porous membrane (5) is the inner layer, the outermost layer (7) is in contact with the transplanted site, and the innermost layer (8) is encapsulated. It touches the buried room.
- the porous membrane needs to have a function of suppressing cell infiltration from the recipient and preventing leakage of the cells to be transplanted, so that the pore diameter smaller than the cell diameter is preferably 5 ⁇ m or less.
- the membrane material a material having excellent biocompatibility that does not easily cause adhesion or inflammation with the tissue surrounding the transplantation of the recipient is desirable, and for example, ethylene-vinyl alcohol copolymer or cellulose is desirable.
- the film thickness of the multi-layered membrane is preferably as thin as possible, 100 ⁇ m or less, considering the material diffusion efficiency of the physiologically active substance from the implant.
- a fiber structure is made by adhering or entwining fibers by thermal, mechanical or chemical action, and by adjusting the texture (weight per unit area) according to the fiber diameter and amount, in addition to strength, It is possible to control the transmittance and filterability.
- the basis weight for example, 10 to 200 g / m 2 is preferable, and 50 to 150 g / m 2 is more preferable.
- the basis weight can be measured by cutting out a fiber structure having a predetermined area and weighing the fiber structure.
- the fiber structure preferably has an average pore size of 1 to 100 ⁇ m, more preferably 1 to 50 ⁇ m, from the viewpoint of retention of the cell mass to be transplanted.
- the average pore size can be measured by the method described in JIS K 3832-1990 (test solution: distilled water, test gas: air, method of moistening the test filter: method B).
- Figure 2. Shows a conceptual diagram in which a porous membrane, which is an outer layer, and a fiber structure are bonded and fixed by thermal, mechanical, or chemical action to form a multi-layered structure.
- the thickness of the fiber structure is preferably as thin as possible of 100 ⁇ m or less in consideration of the material diffusion efficiency of the physiologically active substance from the implant, but the main purpose of the multi-layered fiber structure is to include a porous membrane. It is necessary to fully consider that it is an improvement in the durability of the immune isolation membrane.
- the fiber material of the fiber structure a material having excellent biocompatibility is desirable as in the case of the porous film, but in the case of FIG. 3, the contact with the recipient is the porous film which is the outermost layer. Therefore, this does not apply as long as the material does not adversely affect the implant.
- the outermost layer is a fiber structure, it is desirable that the fiber material of the fiber structure is also a material having excellent biocompatibility. It is also desirable to smooth the surface of the fiber structure by thermal, mechanical or chemical treatment.
- the material having excellent biocompatibility include an ethylene-vinyl alcohol copolymer.
- FIG. 5 shows a composite layer in which a porous film (10) is directly coated on a base material of a fiber structure (9).
- the difference from FIGS. 3 and 4 is not a two-layer structure in which the fiber structure and the porous film are separately prepared and bonded, but a one-layer structure in which the porous film exists in the fiber structure of the fiber structure. It is in the point that it is.
- a polymer solution is applied onto the base material of the fiber structure, the polymer raw material is solidified by phase separation, which is a phase transition phenomenon, and a porous film is formed between the short fibers of the fiber structure. It becomes possible to form.
- a fiber structure is used as a base material, and a solution of a porous membrane constituent polymer is applied and impregnated, and then the polymer is exposed to an insoluble poor solvent or a low temperature environment.
- the porous membrane layer is multi-layered on the surface of the fiber structure or inside the fiber structure.
- the thickness of the porous membrane is determined by the cloth thickness of the fiber structure, and it is possible to reduce the thickness of the immunoseparator membrane as compared with FIGS. 3 and 4, and at the same time, the fiber structure can be made smaller. It is possible to improve the strength of the porous membrane depending on the strength of the porous membrane.
- the outermost layer surface (11) has a porous film (10) covering the fiber structure (9), and the innermost layer surface (12) is either the porous film (10) or the fiber structure (9). But it's okay.
- the fiber material of the fiber structure a material having excellent biocompatibility is desirable as in the case of the porous film, but since the contact with the recipient is the porous film which is the outermost layer, the porous film is a living body.
- a material having excellent compatibility is desirable, and the fiber structure is not limited to this as long as it is a material that does not adversely affect the implant.
- FIG. 6 shows the multi-layering of the porous membrane (13) and the hydrogel (15).
- the hydrogel (15) is impregnated and immobilized (14) on the porous membrane (13), the outermost layer surface (16) is composed of the porous membrane (10), and the innermost layer surface is the hydrogel (14). It is composed of 17).
- It is an immunoisolation membrane formed by forming a hydrogel layer on a porous membrane layer.
- the thickness of the multilayer layer of the hydrogel constituting the immunoisolation membrane and the porous membrane is not particularly limited, but is preferably 10 ⁇ m or more and 300 ⁇ m or less.
- the porous membrane needs to have a function of suppressing cell infiltration from the recipient and preventing leakage of the cells to be transplanted, so that the pore diameter smaller than the cell diameter is preferably 5 ⁇ m or less.
- the membrane material a material having excellent biocompatibility that does not easily cause adhesion or inflammation with the tissue surrounding the transplantation of the recipient is desirable, and for example, ethylene-vinyl alcohol copolymer or cellulose is desirable.
- the porous membrane Although cell infiltration and cell leakage can be suppressed by the porous membrane, it is easy to suppress infiltration of immune system humoral factors such as IgG antibody without suppressing the permeability of necessary bioactive substances. Not. Therefore, by adjusting the gel strength or crosslink density of the hydrogel impregnated and fixed in the porous membrane, the infiltration of immune system humoral factors such as IgG antibody is suppressed without suppressing the transmittance of the physiologically active substance. Is possible.
- Preferred examples of the hydrogel include polyvinyl alcohol-based polymers, chitosan, alginate and the like.
- a hydrosol solution is directly applied to the porous membrane, and hydrogelization is performed by heat, temperature, light or chemical action to form multiple layers.
- a polymer solution of a porous film is directly applied, and the polymer raw material is solidified by phase separation, which is a phase transition phenomenon, and the porous film is made into short fibers of a fiber structure. It can be formed between them.
- a pretreatment for lowering the water content by pre-drying the hydrogel may be required.
- the outer layer, the porous membrane is preferably made of a material that is more biocompatible than hydrogel, and also plays a role in preventing adhesion of hydrogel to the recipient transplant site tissue and the induction of inflammation.
- FIG. 7 shows the multi-layering of the fiber structure (18) and the hydrogel (19).
- the hydrogel (19) is impregnated and fixed to the fiber structure (18), the outermost layer surface (20) is composed of the fiber structure (18), and the innermost layer surface (21) is attached to the hydrogel (19). It is composed of. It is an immunoisolation membrane formed by forming a hydrogel layer on a fiber structure layer.
- the thickness of the multilayer of the fibrous structure constituting the immunoseparator membrane and the hydrogel is not particularly limited, but is preferably 10 ⁇ m or more and 300 ⁇ m or less.
- the fiber structure monolayer it is not easy to suppress not only cell infiltration and cell leakage but also the permeability of necessary bioactive substances and the infiltration of immune system humoral factors such as IgG antibody. .. Therefore, by adjusting the gel strength or cross-linking density of the hydrogel impregnated and fixed in the fiber structure, in addition to cell infiltration and cell leakage, like an IgG antibody, without suppressing the permeability of the physiologically active substance. It is possible to suppress infiltration of immune system humoral factors.
- Preferred examples of the hydrogel include polyvinyl alcohol-based polymers, chitosan, alginate and the like.
- the polyvinyl alcohol-based polymer can be produced, for example, by saponifying a polyvinyl ester obtained by polymerizing a vinyl ester-based monomer and converting the ester group in the polyvinyl ester into a hydroxyl group.
- vinyl ester-based monomer examples include vinyl formate, vinyl acetate, vinyl propionate, n-vinyl butyrate, vinyl isobutyrate, vinyl pivalate, vinyl versatic acid, vinyl caproate, vinyl caprilate, and vinyl caprate.
- Alibi-vinyl esters such as vinyl laurate, vinyl myristate, vinyl palmitate, vinyl stearate, and vinyl oleate; aromatic vinyl esters such as vinyl benzoate and the like.
- One of these may be used alone or in combination of two or more.
- the polyvinyl ester is preferably polyvinyl acetate obtained by polymerizing vinyl acetate.
- the polyvinyl ester may contain a structural unit derived from a monomer other than the vinyl ester-based monomer, if necessary, as long as the effect of the present invention is not impaired.
- the other monomer include ⁇ -olefins such as ethylene, propylene, n-butyl and isobutylene; acrylic acid or a salt thereof; methyl acrylate, ethyl acrylate, n-propyl acrylate, i-acrylate.
- Acrylic acid alkyl esters such as propyl, n-butyl acrylate, i-butyl acrylate, t-butyl acrylate, 2-ethylhexyl acrylate, dodecyl acrylate, octadecyl acrylate; methacrylic acid or a salt thereof; methyl methacrylate , Ethyl methacrylate, n-propyl methacrylate, i-propyl methacrylate, n-butyl methacrylate, i-butyl methacrylate, t-butyl methacrylate, 2-ethylhexyl methacrylate, dodecyl methacrylate, octadecyl methacrylate, etc.
- Alkyl methacrylate esters acrylamide, N-methylacrylamide, N-ethylacrylamide, N, N-dimethylacrylamide, diacetoneacrylamide, acrylamidepropanesulfonic acid or its salts, acrylamidepropyldimethylamine or its salts or quaternary salts, N -Acrylamide derivatives such as methylolacrylamide or derivatives thereof; methacrylamide, N-methylmethacrylate, N-ethylmethacrylate, methacrylate propanesulfonic acid or a salt thereof, methacrylamidepropyldimethylamine or a salt thereof or a quaternary salt, N- Methylamide derivatives such as methylolmethacrylamide or derivatives thereof; N-vinylamide derivatives such as N-vinylformamide and N-vinylacetamide; methylvinyl ether, ethylvinyl ether, n-propylvinyl ether, i-propy
- the average degree of polymerization of the polyvinyl alcohol polymer in the present specification means the average degree of polymerization measured according to JIS K 6726: 1994 as described above. Specifically, it can be obtained from the ultimate viscosity measured in water at 30 ° C. after saponifying and purifying the raw material PVA.
- the saponification degree of the polyvinyl alcohol-based polymer is preferably 50 mol% or more, more preferably 60 mol% or more, still more preferably 65 mol% or more, from the viewpoint of improving the water solubility of the polyvinyl alcohol-based polymer.
- the saponification degree of the polyvinyl alcohol-based polymer is preferably 99 mol% or less.
- the degree of saponification of a polyvinyl alcohol-based polymer is the vinyl with respect to the total number of moles of structural units (for example, vinyl acetate units) and vinyl alcohol units that can be converted into vinyl alcohol units by saponification in the raw material PVA. It means the ratio (mol%) occupied by the number of moles of alcohol unit, and can be measured according to JIS K 6726: 1994.
- a compound containing an ethylenically unsaturated group and a glycidyl group in the molecule (for example, glycidyl (meth) acrylate, allyl glycidyl ether, etc.) is added to the hydroxyl group, which is a side chain of the polyvinyl alcohol-based polymer, as a base.
- a (meth) acryloyl group and / or an allylic group can be introduced.
- a hydrosol solution is directly applied to the fiber structure, and hydrogelization is performed by heat, temperature, light or chemical action to form a multi-layer.
- the fiber structure as the outer layer is preferably made of a material having better biocompatibility than hydrogel, and examples thereof include ethylene-vinyl alcohol copolymers. It is also desirable to smooth the surface of the outermost fiber structure by thermal, mechanical or chemical treatment, as it also plays a role in preventing adhesion of the hydrogel to the recipient tissue and the induction of inflammation.
- FIG. 8 shows a composite layer in which the multilayer devices of FIGS. 3 and 7 are composited, and the outermost layer surface (22) is composed of a porous film and the innermost layer surface (23) is composed of hydrogel.
- a hydrosol solution is applied to the fibrous structure portion of the composite layer of the porous film and the fibrous structure, and the hydrogel is formed by heat, temperature, light or chemical action to form a multi-layer.
- the three-layer structure has stronger immunoisolation than the two-layer structure, and the strength as an immunoseparation membrane is also improved.
- the compatibility between permeability and immunoisolation can be adjusted by adjusting the pore size of the porous membrane, which is the outer layer, and the gel strength and degree of cross-linking of the hydrogel, which is the inner layer.
- FIG. 9 shows a composite layer in which the multilayer devices of FIGS. 5 and 6 are composited, and the outermost layer surface (24) is composed of a porous film, and the innermost layer surface is composed of (25) and hydrogel.
- the immunoisolation property becomes stronger and the strength as an immunoseparation membrane is also improved.
- the compatibility between permeability and immunoisolation can be adjusted by adjusting the pore size of the porous membrane, which is the outer layer, and the gel strength and degree of cross-linking of the hydrogel, which is the inner layer.
- Example 1 (bonding and multi-layering) 1) A porous film (average pore size 1.8 ⁇ m, maximum pore size 3.4 ⁇ m) formed by a polymer phase separation reaction using a multilayered ethylene-vinyl alcohol copolymer and an ethylene-vinyl alcohol copolymer. It was multi-layered with a non-woven fabric (grain size 51.5 g / m 2 , average pore size 20 ⁇ m) prepared by the melt blow method.
- a porous membrane is layered on a non-woven fabric that has been sprayed with a mist of dimethyl sulfoxide containing 5 wt% ion-exchanged water on the junction with the porous membrane, and heated at 60 ° C. Pressurized from the non-woven fabric side at a pressure of 200 kg / cm 2 and crimped.
- a bag-shaped device consisting of a porous membrane and a multi-layer membrane encapsulating mouse fibroblast NIH / 3T3 (2 * 10 6 ) was prepared, placed in a well of a 6-well plate and cultured, and cultured on day 7.
- a bag-shaped device consisting of a porous membrane and a multi-layer membrane encapsulating mouse fibroblast NIH / 3T3 (2 * 10 6 ) was prepared, placed in a well of a 6-well plate and cultured, and cultured on day 7.
- Example 2 (impregnated multi-layering) A non-woven fabric prepared by the melt blow method using polypropylene fibers was used as a base material, and a porous film was formed on the non-woven fabric by a polymer phase separation reaction using an ethylene-vinyl alcohol copolymer.
- a 200 ⁇ m thick polypropylene non-woven fabric was used for the trial production.
- the tensile strength of the non-woven fabric was 5 MPa.
- the non-woven fabric is immersed in a dimethyl sulfoxide solution of 20 wt% ethylene-vinyl alcohol copolymer heated to 80 ° C for 90 seconds, and then coagulated liquid DMSO / water 50%, 40 ° C for 15 minutes.
- a porous film was formed by a phase separation reaction. Due to the impregnation multi-layering, the film thickness was 200 ⁇ m, which was the same as that of the non-woven fabric single layer, and the tensile strength was improved from 1.5 MPa of the porous membrane single layer to 5 MPa.
- the average pore diameter was 0.1 ⁇ m and the maximum pore diameter was 1.5 ⁇ m.
- Example 3 (membrane + PVA hydrogel) 1) Multilayering A porous film formed by a polymer phase separation reaction using an ethylene-vinyl alcohol copolymer was layered with a hydrogel containing polyvinyl alcohol as a main component.
- a 100 ⁇ m thick porous membrane was used for the trial production.
- water-soluble light so as to be 0.1% by mass with respect to 10% of a polyvinyl alcohol (average polymerization degree 1700, saponification degree 98.0-99.0 mol%, methacryl group modification rate 1.2 mol%) solution modified with a methacryloyl group.
- a sol dissolved by adding a lithium phosphinic acid salt of phenyl (2,4,6-trimethylbenzoyl) as a radical polymerization initiator was used.
- This sol was coated on a PET film with a bar coater to a thickness of 200 ⁇ m, a porous film was placed on the sol, and the sol and the porous film were brought into close contact with each other with a laminator. Then, with the sol side facing up, a hydrogel was formed on the porous membrane by irradiating with light of 365 nm at an intensity of 15 mW / cm 2 for 3 minutes.
- the permeability of glucose was 93.4%
- the permeability of insulin was 62.8%
- the permeability of IgG was 2.5% (Table 2).
- a bag-shaped device in which mouse fibroblasts NIH / 3T3 (2 * 10 6 cells) were encapsulated in the multilayer membrane was prepared, placed in a well on a 6-well plate and cultured, and the culture surface was observed on day 7.
- the culture surface was observed on day 7.
- no cell infiltration was observed as in the case of the porous membrane monolayer.
- the conventional device for embedding the implant in the hydrogel has a lower limit on the thickness of the hydrogel in order to completely embed the implant.
- a thickness of about 500 ⁇ m is required.
- a hydrogel having a thickness of 500 ⁇ m was prepared using the above-mentioned polyvinyl alcohol modified with a methacryloyl group and a substance permeability test was performed, the permeability of glucose was 54% and the permeability of insulin was 6.8%. From this, it was confirmed that the composite membrane of the thin layer PVA gel shows higher substance diffusion efficiency than the conventional device.
- Example 4 (nonwoven fabric + PVA hydrogel) A non-woven fabric prepared by a melt blow method using an ethylene-vinyl alcohol copolymer and a hydrogel containing polyvinyl alcohol as a main component were multi-layered.
- a 200 ⁇ m thick ethylene-vinyl alcohol copolymer non-woven fabric was used for the trial production.
- the tensile strength of the non-woven fabric was 5 MPa.
- the polyvinyl alcohol solution modified with the methacryloyl group described in Example 3 was used for the multi-layering.
- a hydrogel was formed on the non-woven fabric film by the same method as in Example 3.
- the permeability of glucose, insulin, and IgG in the multi-layered membrane was measured in the same manner as in the method described in Example 3.
- the glucose permeability was 95.3% and the insulin permeability was 74.3%.
- the transmittance of IgG was 19.7% with the non-woven fabric alone, but it could be reduced to 7.8% by multi-layering with hydrogel (Table 3).
- a bag-shaped device in which mouse fibroblasts NIH / 3T3 (2 * 10 6 cells) were encapsulated in the multilayer membrane was prepared, placed in a well of a 6-well plate and cultured, and the culture surface was observed on day 7.
- the culture surface was observed on day 7.
- Example 5 (impregnated double glazing + PVA hydrogel) It is possible to carry out multi-layering of the multi-layer film produced in Example 2 and a hydrogel containing polyvinyl alcohol as a main component. For multi-layering, a hydrogel can be formed on the multi-layer film prepared in Example 2 by using the same method as in Example 3.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Memory System Of A Hierarchy Structure (AREA)
Abstract
Description
本出願は、2020年10月28日に出願された、日本国特許出願第2020-180919号明細書(その開示全体が参照により本明細書中に援用される)に基づく優先権を主張する。本発明は、免疫隔離デバイスに関する。
細胞塊などの内部ネクローシスは500μm以上の直径を超えると惹起されるとされており、包埋細胞の被移植体への生着維持と生理活性物質の放出を容易に達成するには、デバイス全体の厚みを適切に制御する必要があり、デバイスを構成する免疫隔離膜は可能な限り薄膜であることが望ましい。一方で、体内への移植を想定した場合、デバイスの破れ、捻じれなどを防止する膜強度及び耐久性の向上も必要となるが、薄膜化と耐久性向上を両立することは容易では無い。
〔1〕被移植物の包埋室を備え、前記包埋室は免疫隔離膜で覆われてなる免疫隔離デバイス。
〔2〕前記免疫隔離膜が、繊維構造体、多孔質膜およびハイドロゲルからなる群から選ばれる少なくとも2種を含む、〔1〕に記載の免疫隔離デバイス。
〔3〕前記免疫隔離膜が、繊維構造体層、多孔質膜層およびハイドロゲル層からなる群から選ばれる少なくとも2層を含む複層化膜である、〔1〕に記載の免疫隔離デバイス。
〔4〕前記免疫隔離膜は、免疫応答細胞と免疫系液性因子の包埋室への侵入を抑制するものである、〔1〕~〔3〕のいずれか1項に記載の免疫隔離デバイス。
〔5〕前記免疫隔離膜は、免疫応答細胞の透過を阻止し、インシュリン及びグルコースの透過率が50%以上であり、且つ免疫系液性因子の透過率が30%以下である、〔1〕~〔4〕のいずれか1項に記載の免疫隔離デバイス。
〔6〕前記免疫隔離膜は、インシュリン及びグルコースの透過率が50%以上であり、且つ免疫系液性因子の透過率が10%以下である〔5〕に記載の免疫隔離デバイス。
〔7〕前記免疫隔離膜の引張強度が1MPa以上である、〔1〕~〔6〕のいずれか1項に記載の免疫隔離デバイス。
〔8〕前記免疫隔離膜が、多孔質膜層及び/又はハイドロゲル層を繊維構造体層上に形成してなる、〔1〕~〔7〕のいずれか1項に記載の免疫隔離デバイス。
〔9〕前記免疫隔離膜が、ハイドロゲル層を多孔質膜層上に形成してなる、〔1〕~〔7〕のいずれか1項に記載の免疫隔離デバイス。
〔10〕繊維構造体を基材とし、高分子原料を繊維構造体へ塗布し、多孔質膜を繊維構造体の短繊維間に形成させた前記免疫隔離膜を含む、〔1〕~〔8〕のいずれか1項に記載の免疫隔離デバイス。
〔11〕前記免疫隔離膜が、繊維構造体を基材とし、ハイドロゾル溶液を直接繊維構造体へ塗布し、熱、温度、光または化学的な作用によって、ハイドロゲル化させてなる、〔1〕~〔10〕のいずれか1項に記載の免疫隔離デバイス。
〔12〕多孔質膜を基材とし、ハイドロゾル溶液を直接多孔質膜へ塗布し、熱、温度、光または化学的な作用によって、ハイドロゲル化させた前記免疫隔離膜を含む、〔1〕~〔9〕のいずれか1項に記載の免疫隔離デバイス。
〔13〕前記免疫隔離膜が、エチレン―ビニルアルコール共重合体の多孔質膜を含む、〔1〕~〔10〕、〔12〕のいずれか1項に記載の免疫隔離デバイス。
〔14〕前記ハイドロゲルが、ポリビニルアルコール系高分子で構成される、〔1〕~〔13〕のいずれか1項に記載の免疫隔離デバイス。
〔15〕前記免疫隔離膜の最外層表面が、エチレン―ビニルアルコール共重合体で構成される、〔1〕~〔14〕のいずれか1項に記載の免疫隔離デバイス。
〔16〕前記免疫隔離膜の最外層表面が、エチレン―ビニルアルコール共重合体の繊維構造体であって、且つ表面が平滑に圧縮加工されてなる、〔1〕~〔15〕のいずれか1項に記載の免疫隔離デバイス。
〔17〕前記免疫隔離膜の厚みが10μm以上300μm以下である、〔1〕~〔16〕のいずれか1項に記載の免疫隔離デバイス。
〔18〕前記免疫隔離膜を構成するハイドロゲルと多孔質膜との複層厚みが、10μm以上300μm以下である、〔1〕~〔17〕のいずれか1項に記載の免疫隔離デバイス。
〔19〕前記免疫隔離膜を構成する繊維構造体と多孔質膜との複層厚みが、10μm以上300 μm以下である〔1〕~〔18〕のいずれか1項に記載の免疫隔離デバイス。
〔20〕前記免疫隔離膜を構成する繊維構造体とハイドロゲルとの複層厚みが、10μm以上300μm以下である、〔1〕~〔19〕のいずれか1項に記載の免疫隔離デバイス。
本発明の免疫隔離デバイスは、被移植物を包埋することが可能な包埋室と免疫隔離膜を備え、前記包埋室は免疫隔離膜で覆われることで、免疫細胞とサイトカインの包埋室への侵入を抑制することができる。また、免疫隔離膜は、繊維構造体 、多孔質膜およびハイドロゲルからなる群から選ばれる少なくとも2種を含む。
、2つのハイドロゲル層の間に多孔質膜層又は繊維構造体層を介在させてもよい。
[各物質の透過率(%)]=[測定24時間後のチャンバーBにおける各物質の濃度]/{[測定開始時のチャンバーAにおける各物質の濃度]÷2}×100
(i)繊維構造体またはハイドロゲルを基材として、多孔質膜を繊維構造体上に製膜する。または
(ii)繊維構造体を基材として、繊維構造体にハイドロゲルを含浸形成させる。または
(iii)多孔質膜を基材として、多孔質膜上にハイドロゲルを含浸させる。または
(iv)繊維構造体を基材として、多孔質膜を製膜させ、更にハイドロゲルを形成させる。
3層構造にすることにより、2層構造よりもより免疫隔離性がより強くなるとともに、免疫隔離膜としての強度も向上する。透過率と免疫隔離性の両立は、外層である多孔質膜の孔径と内層であるハイドロゲルのゲル強度や架橋度により調整が可能である。
実施例1(貼り合わせ複層化)
1)複層化
エチレン―ビニルアルコール共重合体を用いた高分子相分離反応にて製膜した多孔質膜(平均孔径1.8μm、最大孔径3.4μm)と、同じくエチレン―ビニルアルコール共重合体を用いてメルトブロー法にて作製した不織布(目付量51.5g/m2、平均ポアサイズ20μm)との複層化を実施した。
当該複層化により、引張強度は多孔質膜単層の1.5MPaから5MPaに向上した。
<測定条件>
装置名:万能試験機210XL型(インテスコ製)
試験速度:50mm/min
試験片形状:タイプ5
試験温度:23.0℃
この多孔質膜と不織布についてグルコース、インシュリン、およびIgGの透過率を測定した。それぞれの透過率から、複層化した場合の透過率の推定値を算出した。なお、推定値は、複層化によって多孔質膜の孔が接合界面で潰れないことと仮定した場合とする。
測定方法としては、サンプルをチャンバーaとbの間(図10)に挟み、チャンバーaに、インシュリン(30 U/L)、グルコース(5 mg/mL)、およびIgG(0.5 μg/mL)を調合した後、37℃恒温下にてスターラー攪拌し、24時間後にチャンバーb内のインシュリン、グルコースおよびIgGの濃度変化をELISA法にて測定し、各物質の透過率を算出した(表1)。
ポリプロピレン繊維を用いてメルトブロー法にて作製した不織布を基材とし、当該不織布に、同じくエチレン―ビニルアルコール共重合体を用いた高分子相分離反応により多孔質膜を製膜した。
当該含浸複層化により、膜厚は不織布単層と同等の200μmであり、引張強度は多孔質膜単層の1.5MPaから5MPaに向上した。また平均孔径は0.1μm、最大孔径は1.5μmであった。
1)複層化
エチレン―ビニルアルコール共重合体を用いた高分子相分離反応にて製膜した多孔質膜と、ポリビニルアルコールを主成分とするハイドロゲルとの複層化を実施した。
この複層化膜についてグルコース、インシュリン、およびIgGの透過率を測定した。サンプルをチャンバーaとbの間(図10)に挟み、チャンバーaに、インシュリン(30 U/L)、グルコース(5 mg/mL)、およびIgG(0.5 μg/mL)を調合した後、37℃恒温下にてスターラー攪拌し、24時間後にチャンバーb内のインシュリン、グルコースおよびIgGの濃度変化をELISA法にて測定し、各物質の透過率を算出した。その結果、グルコースの透過率は93.4%、インシュリンの透過率は62.8%、IgGの透過率は2.5%であった(表2)。また、当該複層膜にマウス線維芽細胞NIH/3T3(2*106個)を封入した袋状デバイスを作製し、6-well plateのウェルに入れて培養し、day7に培養表面を観察し、ウェルに接着した細胞および培養上清を回収して細胞核を計数した結果、多孔質膜単層と同様に、細胞浸潤を認めなかった。
エチレン―ビニルアルコール共重合体を用いてメルトブロー法にて作製した不織布と、ポリビニルアルコールを主成分とするハイドロゲルとの複層化を実施した。
実施例3に記載の方法と同様に、当該複層化膜のグルコース、インシュリン、およびIgGの透過率を測定した。グルコースの透過率は95.3%、インシュリンの透過率は74.3%であった。また、不織布単独ではIgGの透過率は19.7%であったが、ハイドロゲルと複層化することで7.8%に低下させることができた(表3)。
実施例2で作製した複層膜と、ポリビニルアルコールを主成分とするハイドロゲルとの複層化を実施することができる。複層化には、実施例3と同様の方法を用いて、ハイドロゲルを実施例2で作製した複層膜上に形成させることができる。
a2 免疫隔離膜
a3 溶着
a4 一定距離
b1 免疫隔離膜
b2 免疫隔離膜
b3 免疫隔離膜
b4 管状内部
1 多孔質膜
2 繊維構造体
3 最外層
4 最内層
5 多孔質膜
6 繊維構造体
7 最外層
8 最内層
9 繊維構造体
10 多孔質膜
11 最外層表面
12 最内層表面
13 多孔質膜
14 含浸固定化
15 ハイドロゲル
16 最外層表面
17 ハイドロゲル
18 繊維構造体
19 ハイドロゲル
20 最外層表面
21 最内層表面
22 最外層表面
23 最内層表面
24 最外層表面
25 最内層表面
Claims (20)
- 被移植物の包埋室を備え、前記包埋室は免疫隔離膜で覆われてなる免疫隔離デバイス。
- 前記免疫隔離膜が、繊維構造体、多孔質膜およびハイドロゲルからなる群から選ばれる少なくとも2種を含む、請求項1に記載の免疫隔離デバイス。
- 前記免疫隔離膜が、繊維構造体層、多孔質膜層およびハイドロゲル層からなる群から選ばれる少なくとも2層を含む複層化膜である、請求項1に記載の免疫隔離デバイス。
- 前記免疫隔離膜は、免疫応答細胞と免疫系液性因子の包埋室への侵入を抑制するものである、請求項1~3のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜は、免疫応答細胞の透過を阻止し、インシュリン及びグルコースの透過率が50%以上であり、且つ免疫系液性因子の透過率が30%以下である、請求項1~4のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜は、インシュリン及びグルコースの透過率が50%以上であり、且つ免疫系液性因子の透過率が10%以下である請求項5に記載の免疫隔離デバイス。
- 前記免疫隔離膜の引張強度が1MPa以上である、請求項1~6のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜が、多孔質膜層及び/又はハイドロゲル層を繊維構造体層上に形成してなる、請求項1~7のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜が、ハイドロゲル層を多孔質膜層上に形成してなる、請求項1~7のいずれか1項に記載の免疫隔離デバイス。
- 繊維構造体を基材とし、高分子原料を繊維構造体へ塗布し、多孔質膜を繊維構造体の短繊維間に形成させた前記免疫隔離膜を含む、請求項1~8のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜が、繊維構造体を基材とし、ハイドロゾル溶液を直接繊維構造体へ塗布し、熱、温度、光または化学的な作用によって、ハイドロゲル化させてなる、請求項1~10のいずれか1項に記載の免疫隔離デバイス。
- 多孔質膜を基材とし、ハイドロゾル溶液を直接多孔質膜へ塗布し、熱、温度、光または化学的な作用によって、ハイドロゲル化させた前記免疫隔離膜を含む、請求項1~9のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜が、エチレン―ビニルアルコール共重合体の多孔質膜を含む、請求項1~10、12のいずれか1項に記載の免疫隔離デバイス。
- 前記ハイドロゲルが、ポリビニルアルコール系高分子で構成される、請求項1~13のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜の最外層表面が、エチレン―ビニルアルコール共重合体で構成される、請求項1~14のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜の最外層表面が、エチレン―ビニルアルコール共重合体の繊維構造体であって、且つ表面が平滑に圧縮加工されてなる、請求項1~15のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜の厚みが10μm以上300μm以下である、請求項1~16のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜を構成するハイドロゲルと多孔質膜との複層厚みが、10μm以上300μm以下である、請求項1~17のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜を構成する繊維構造体と多孔質膜との複層厚みが、10μm以上300μm以下である請求項1~18のいずれか1項に記載の免疫隔離デバイス。
- 前記免疫隔離膜を構成する繊維構造体とハイドロゲルとの複層厚みが、10μm以上300μm 以下である、請求項1~19のいずれか1項に記載の免疫隔離デバイス。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21886315.7A EP4238591A1 (en) | 2020-10-28 | 2021-10-28 | Immunoisolation device |
CA3200418A CA3200418A1 (en) | 2020-10-28 | 2021-10-28 | Immunoisolation device |
US18/033,974 US20230414832A1 (en) | 2020-10-28 | 2021-10-28 | Immunoisolation device |
AU2021372119A AU2021372119A1 (en) | 2020-10-28 | 2021-10-28 | Immunoisolation device |
CN202180087916.3A CN116710155A (zh) | 2020-10-28 | 2021-10-28 | 免疫隔离装置 |
JP2022559228A JPWO2022092198A1 (ja) | 2020-10-28 | 2021-10-28 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020180919 | 2020-10-28 | ||
JP2020-180919 | 2020-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022092198A1 true WO2022092198A1 (ja) | 2022-05-05 |
Family
ID=81382561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/039818 WO2022092198A1 (ja) | 2020-10-28 | 2021-10-28 | 免疫隔離デバイス |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230414832A1 (ja) |
EP (1) | EP4238591A1 (ja) |
JP (1) | JPWO2022092198A1 (ja) |
CN (1) | CN116710155A (ja) |
AU (1) | AU2021372119A1 (ja) |
CA (1) | CA3200418A1 (ja) |
WO (1) | WO2022092198A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012133631A1 (ja) * | 2011-03-30 | 2012-10-04 | 株式会社クラレ | フィルター用濾材および該濾材を備える水濾過装置 |
KR20150136673A (ko) * | 2014-05-27 | 2015-12-08 | 인하대학교 산학협력단 | 직물-하이드로겔 복합분리막 및 직물-하이드로겔 복합분리막을 이용한 미세조류 배양방법 |
WO2019044990A1 (ja) * | 2017-08-30 | 2019-03-07 | 富士フイルム株式会社 | 細胞移植用デバイスおよびその製造方法 |
WO2019106996A1 (ja) * | 2017-11-30 | 2019-06-06 | 株式会社日立製作所 | 免疫隔離デバイス |
JP2020180919A (ja) | 2019-04-26 | 2020-11-05 | 株式会社キーエンス | 光学式変位計 |
-
2021
- 2021-10-28 AU AU2021372119A patent/AU2021372119A1/en active Pending
- 2021-10-28 US US18/033,974 patent/US20230414832A1/en active Pending
- 2021-10-28 CN CN202180087916.3A patent/CN116710155A/zh active Pending
- 2021-10-28 EP EP21886315.7A patent/EP4238591A1/en active Pending
- 2021-10-28 JP JP2022559228A patent/JPWO2022092198A1/ja active Pending
- 2021-10-28 WO PCT/JP2021/039818 patent/WO2022092198A1/ja active Application Filing
- 2021-10-28 CA CA3200418A patent/CA3200418A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012133631A1 (ja) * | 2011-03-30 | 2012-10-04 | 株式会社クラレ | フィルター用濾材および該濾材を備える水濾過装置 |
KR20150136673A (ko) * | 2014-05-27 | 2015-12-08 | 인하대학교 산학협력단 | 직물-하이드로겔 복합분리막 및 직물-하이드로겔 복합분리막을 이용한 미세조류 배양방법 |
WO2019044990A1 (ja) * | 2017-08-30 | 2019-03-07 | 富士フイルム株式会社 | 細胞移植用デバイスおよびその製造方法 |
WO2019106996A1 (ja) * | 2017-11-30 | 2019-06-06 | 株式会社日立製作所 | 免疫隔離デバイス |
JP2020180919A (ja) | 2019-04-26 | 2020-11-05 | 株式会社キーエンス | 光学式変位計 |
Also Published As
Publication number | Publication date |
---|---|
AU2021372119A1 (en) | 2023-06-22 |
JPWO2022092198A1 (ja) | 2022-05-05 |
EP4238591A1 (en) | 2023-09-06 |
CN116710155A (zh) | 2023-09-05 |
US20230414832A1 (en) | 2023-12-28 |
CA3200418A1 (en) | 2022-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101685248B1 (ko) | 다층의 전기방사 섬유가 복합된 하이드로젤 | |
US5902745A (en) | Cell encapsulation device | |
CN110772661A (zh) | 一种无毒环保溶剂型双层纳米纤维皮肤敷料及其制备方法 | |
JP2021104368A (ja) | 移植型カプセル化デバイス | |
Buriuli et al. | Polyelectrolyte complexes (PECs) for biomedical applications | |
Chen et al. | Designing biomimetic scaffolds for skin tissue engineering | |
GB2580473A (en) | Membrane | |
CN114870084A (zh) | 混合中空微胶囊,包含其的软组织用支架及其的制备方法 | |
US20200360566A1 (en) | Immunoisolation device | |
US20200179121A1 (en) | An implantable medical device | |
Soman et al. | Interpenetrating polymer network (Ipn)-hydrogels | |
US20210316043A1 (en) | Cell transplantation kit, method for producing sac-shaped structure, and therapeutic agent for diabetes | |
WO2022092198A1 (ja) | 免疫隔離デバイス | |
Somya et al. | Interpenetrating polymer network-based drug delivery systems: emerging applications and recent patents | |
JP6920681B2 (ja) | 移植用デバイス及びその製造方法並びにバイオ人工臓器の製造方法 | |
WO2023210765A1 (ja) | 免疫隔離デバイス | |
EP4238592A1 (en) | Hydrogel for cell embedding, immunoisolation device, and transplant material | |
WO2023210775A1 (ja) | 免疫隔離デバイス | |
JP2022071773A (ja) | 血管新生を惹起することができる免疫隔離デバイス | |
KR102430543B1 (ko) | 하이드로겔 스폰지 내 h2o2 함입 plga 마이크로구체를 포함하는 창상피복재 및 이의 제조방법 | |
KR100431244B1 (ko) | 생분해성 고분자 다공성 지지체의 친수화 처리방법 | |
JP2004097687A (ja) | 生体用樹脂基材及びその製造方法 | |
EP3634304B1 (en) | An implantable medical device | |
JP6854345B2 (ja) | 移植用チャンバーおよび移植用デバイス | |
JP2001346866A (ja) | ハイブリッド樹脂材料およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21886315 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022559228 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18033974 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 3200418 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021886315 Country of ref document: EP Effective date: 20230530 |
|
ENP | Entry into the national phase |
Ref document number: 2021372119 Country of ref document: AU Date of ref document: 20211028 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180087916.3 Country of ref document: CN |